Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors

Conclusion: Survivin family proteins are novel effectors of doxorubicin resistance in chemotherapy-naive breast cancer. The incorporation of survivin antagonist(s) in anthracycline-containing regimens may have improved clinical activity in these patients.
Source: Breast Cancer Research - Category: Cancer & Oncology Authors: Source Type: research